Research

Hormonal

Semaglutide (1.0 mg once-weekly) significantly improves fasting and postprandial glucose and lipid metabolism in subjects with obesity, primarily through delayed first-hour gastric emptying and GLP-1 receptor agonism.

For individuals with obesity, semaglutide (1.0 mg weekly) significantly improves how the body handles glucose and fats after eating. This is achieved by slowing down the initial emptying of the stomach, which prevents rapid spikes in blood sugar and lipids. This benefit occurs even in people without diabetes, suggesting it may be a valuable tool for metabolic health in obesity.

GoodSupportsHIGH confidence
Semaglutide improved fasting and postprandial glucose and lipid metabolism. Overall gastric emptying was similar to that with placebo; however, the observed first-hour delay with semaglutide may contribute to a slower entry of glucose into the circulation.
Julie Hjerpsted et al. · Diabetes Obesity and Metabolism · 2017

Why this rating

Randomized, double-blind, placebo-controlled, crossover trial with statistical significance reported for key endpoints.

Source

Semaglutide improves postprandial glucose and lipid metabolism, and delays first‐hour gastric emptying in subjects with obesity

Julie Hjerpsted et al. · Diabetes Obesity and Metabolism · 2017

DOI 10.1111/dom.13120

crossover · n=30Cited 223×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →